CHNUK: Integrated platforms from science to policy in response to antibacterial resistance
Lead Research Organisation:
University of Warwick
Department Name: School of Life Sciences
Abstract
Combating Antimicrobial Resistance (AMR) in China requires a multi-pronged approach that includes the need for new effective antimicrobials.
Traditionally, China has been a major producer of generic antibiotics rather than a developer, but times are changing with new government policies that are beginning to help drive innovation in drug discovery. This includes the structured revitalization of Traditional Chinese Medicines (TCM), which, along with other natural products are known to possess antibacterial activities. It is very clear that effective antimicrobials, both those as monotherapy or in combination therapy, are those that hit multiple targets. Traditional Chinese Medicines (TCM) are by nature combinatorial in their activities and present a golden opportunity for China to take a strategic lead in the development of new effective therapeutics to combat AMR in China.
Here we bring together interdisciplinary teams to deliver state of the art scientific advances and policy expertise across the UK and China; that will help train the next generation of researchers, develop innovative research platforms, and an environment from which (given the support and incentives) antibiotic R&D in China could grow and flourish into a new 'golden age' of discovery. This is potentially achievable, and we will determine the critical pathways and drivers that will influence and enable the discovery, development and delivery of new antibiotics in China.
Six technology, policy, and training platforms provide the framework and foundation for future delivery, and a pipeline for China UK exchange and interaction. 1.Target validation and mechanisms. 2.Assays and screening. 3. Lead development 4. Industry translation 5. Policy. 6. Training and exchange. Exchange will be an important component of the hub enabling interchange of up to 15-20 researchers into the UK or China. This includes cultural orientation, crash course language training and a broad AMR training program at Sheffield for incoming China researchers, plus specialist research training for up to 12 months at hub partners. Our focus will be on 'old' and 'new' targets encompassing our breadth of existing expertise in essential processes, virulence and resistance mechanisms. Our targets will be those within multi-drug resistance in 'ESKAPE' and WHO priority bacteria including Escherichia coli, Helicobacter pylori, Pseudomonas aeruginosa, Salmonella sp. and Staphylococcus aureus. These pathogens are responsible for life-threatening infections in most Chinese hospitals and communities. New topical, gastric and systemic therapeutic interventions are urgently required to reduce transmission and disease.
This CHN UK hub of activity is built from strong university and institute partnerships across Chinese Academy of Sciences (CAS) Shanghai Institue Materia Medica (SIMM), Jilin, Royal Botanic Gardens at Kew, Sheffield, Oxford, Peking, Warwick, Xiamen. These are cornerstoned by national infrastructure support in the UK from the Diamond Light Source synchrotron, Protein Production UK (PPUK) and the Research Complex at Harwell (RCaH), and in China by the Shanghai Synchrotron (SINAP) and national compound collection at SIMM. Furthermore, these will be supported by an international panel of experts from academia and industry. This expertise includes individuals with more than 250 years combined experience in antibiotic discovery, the de novo establishment of a drug discovery institute (H3D) in South Africa, and global AMR industry and policy perspectives from PwC (with significant China expertise) and The Economist Group, both of whom are heavily committed to help encourage the development of global AMR solutions. The Economist Group have already planned a major international AMR workshop (London, Jan 2019) that we will engage with.
A senior management group supported by English and Chinese speaking administrators in Warwick and Sheffield will enable effective program delivery.
Traditionally, China has been a major producer of generic antibiotics rather than a developer, but times are changing with new government policies that are beginning to help drive innovation in drug discovery. This includes the structured revitalization of Traditional Chinese Medicines (TCM), which, along with other natural products are known to possess antibacterial activities. It is very clear that effective antimicrobials, both those as monotherapy or in combination therapy, are those that hit multiple targets. Traditional Chinese Medicines (TCM) are by nature combinatorial in their activities and present a golden opportunity for China to take a strategic lead in the development of new effective therapeutics to combat AMR in China.
Here we bring together interdisciplinary teams to deliver state of the art scientific advances and policy expertise across the UK and China; that will help train the next generation of researchers, develop innovative research platforms, and an environment from which (given the support and incentives) antibiotic R&D in China could grow and flourish into a new 'golden age' of discovery. This is potentially achievable, and we will determine the critical pathways and drivers that will influence and enable the discovery, development and delivery of new antibiotics in China.
Six technology, policy, and training platforms provide the framework and foundation for future delivery, and a pipeline for China UK exchange and interaction. 1.Target validation and mechanisms. 2.Assays and screening. 3. Lead development 4. Industry translation 5. Policy. 6. Training and exchange. Exchange will be an important component of the hub enabling interchange of up to 15-20 researchers into the UK or China. This includes cultural orientation, crash course language training and a broad AMR training program at Sheffield for incoming China researchers, plus specialist research training for up to 12 months at hub partners. Our focus will be on 'old' and 'new' targets encompassing our breadth of existing expertise in essential processes, virulence and resistance mechanisms. Our targets will be those within multi-drug resistance in 'ESKAPE' and WHO priority bacteria including Escherichia coli, Helicobacter pylori, Pseudomonas aeruginosa, Salmonella sp. and Staphylococcus aureus. These pathogens are responsible for life-threatening infections in most Chinese hospitals and communities. New topical, gastric and systemic therapeutic interventions are urgently required to reduce transmission and disease.
This CHN UK hub of activity is built from strong university and institute partnerships across Chinese Academy of Sciences (CAS) Shanghai Institue Materia Medica (SIMM), Jilin, Royal Botanic Gardens at Kew, Sheffield, Oxford, Peking, Warwick, Xiamen. These are cornerstoned by national infrastructure support in the UK from the Diamond Light Source synchrotron, Protein Production UK (PPUK) and the Research Complex at Harwell (RCaH), and in China by the Shanghai Synchrotron (SINAP) and national compound collection at SIMM. Furthermore, these will be supported by an international panel of experts from academia and industry. This expertise includes individuals with more than 250 years combined experience in antibiotic discovery, the de novo establishment of a drug discovery institute (H3D) in South Africa, and global AMR industry and policy perspectives from PwC (with significant China expertise) and The Economist Group, both of whom are heavily committed to help encourage the development of global AMR solutions. The Economist Group have already planned a major international AMR workshop (London, Jan 2019) that we will engage with.
A senior management group supported by English and Chinese speaking administrators in Warwick and Sheffield will enable effective program delivery.
Technical Summary
We will
Bring together China and UK science and policy groups with industry, government advisors and funders, forming hubs to support platforms for fundamental and translational AMR discovery research targeting 'old' and 'new' essential processes, virulence and resistance mechanisms.
Develop new scientific methods and associated software platforms to combine high throughput natural product discovery with rapid chemical progression of fragment compounds from 'hit' to 'lead'.
Establish a China UK discovery pipeline from target to translation, with the combined natural product and fragment based lead discovery being a key element of our broad activities in AMR and allied fields.
Map capabilities and develop policy positions to influence funding and practice that will develop and strengthen the pipeline of AMR discovery R&D in China.
Enable substantive exchange programs to train and inform, across the wider breadth of disciples, the next generation of AMR researchers.
This will
Develop a robust research pipeline of AMR policy and discovery between China and the UK
Develop new capabilities and platforms at major national infrastructure investments (UK and Shanghai synchrotrons), automating high throughput structure determination at Shanghai with technology from the UK, driving the speed of hit chemical progression, and further pushing its bounds of productivity.
Develop a new generation of skilled and interconnected AMR researchers in China with a wide breadth of understanding and deep specialist training in 'state of the art' techniques
Develop new policy positions that will help influence and sustain AMR discovery funding, development and deployment in China.
Bring together China and UK science and policy groups with industry, government advisors and funders, forming hubs to support platforms for fundamental and translational AMR discovery research targeting 'old' and 'new' essential processes, virulence and resistance mechanisms.
Develop new scientific methods and associated software platforms to combine high throughput natural product discovery with rapid chemical progression of fragment compounds from 'hit' to 'lead'.
Establish a China UK discovery pipeline from target to translation, with the combined natural product and fragment based lead discovery being a key element of our broad activities in AMR and allied fields.
Map capabilities and develop policy positions to influence funding and practice that will develop and strengthen the pipeline of AMR discovery R&D in China.
Enable substantive exchange programs to train and inform, across the wider breadth of disciples, the next generation of AMR researchers.
This will
Develop a robust research pipeline of AMR policy and discovery between China and the UK
Develop new capabilities and platforms at major national infrastructure investments (UK and Shanghai synchrotrons), automating high throughput structure determination at Shanghai with technology from the UK, driving the speed of hit chemical progression, and further pushing its bounds of productivity.
Develop a new generation of skilled and interconnected AMR researchers in China with a wide breadth of understanding and deep specialist training in 'state of the art' techniques
Develop new policy positions that will help influence and sustain AMR discovery funding, development and deployment in China.
Planned Impact
The focus of our proposed collaborative CHNUK: Integrated platforms from science to policy in response to antibacterial resistance meets ODA compliance across its main objectives in the promotion of future health and welfare in China, the lives of the most vulnerable people and in future economic development.
The project will use UK strengths in underpinning biology and science policy within UK academic groups and the platforms proposed within this application to maximise China's rich history and resources in natural products and traditional Chinese medicines. The China partners groups recognise these strengths and jointly we have developed an integrated programme of research, innovation and capacity building (from science to policy) to address the pressing need to combat antibiotic resistance in China, and in particular the lives of the most vulnerable people. Furthermore, China partners recognise that up-skilling within this programme will enable the proposed UK technology transfer to be used to its maximum effect. In the short term this, and fundamental research insights from UK research groups, will enable a step change in China researchers capabilities and policy for AMR discovery funding. In the mid to term all of this will enable more effective interaction with the emerging China drug discovery companies. There is already evidence of our China partners interacting with this industry sector in China, not only in the environment around Shanghai high-tech research parks, but also from activities in partners at Jilin and Xiamen. All of this will further accelerate this transfer and economic development underpinned by policy, enabled by the new skills and platforms developed from this programme. In the longer term the advances in knowledge developed by the partnership will help underpin the broader discovery of effective antibiotics in China that will be used to tackle the real and present threat to health in China that currently, disproportionately, afflicts the most vulnerable due to antibiotic resistant bacteria and lack of effect therapies.
The project will use UK strengths in underpinning biology and science policy within UK academic groups and the platforms proposed within this application to maximise China's rich history and resources in natural products and traditional Chinese medicines. The China partners groups recognise these strengths and jointly we have developed an integrated programme of research, innovation and capacity building (from science to policy) to address the pressing need to combat antibiotic resistance in China, and in particular the lives of the most vulnerable people. Furthermore, China partners recognise that up-skilling within this programme will enable the proposed UK technology transfer to be used to its maximum effect. In the short term this, and fundamental research insights from UK research groups, will enable a step change in China researchers capabilities and policy for AMR discovery funding. In the mid to term all of this will enable more effective interaction with the emerging China drug discovery companies. There is already evidence of our China partners interacting with this industry sector in China, not only in the environment around Shanghai high-tech research parks, but also from activities in partners at Jilin and Xiamen. All of this will further accelerate this transfer and economic development underpinned by policy, enabled by the new skills and platforms developed from this programme. In the longer term the advances in knowledge developed by the partnership will help underpin the broader discovery of effective antibiotics in China that will be used to tackle the real and present threat to health in China that currently, disproportionately, afflicts the most vulnerable due to antibiotic resistant bacteria and lack of effect therapies.
Organisations
- University of Warwick (Lead Research Organisation)
- LifeArc (Collaboration)
- AstraZeneca (Collaboration)
- Northeastern University - Boston (Collaboration)
- University College London (Collaboration)
- Shanghai Jiao Tong University (Collaboration)
- Seattle Biomedical Research Institute (Collaboration)
- China Agricultural University (CAU) (Collaboration)
- DIAMOND LIGHT SOURCE (Collaboration)
- Asia–Europe Foundation (ASEF) (Collaboration)
Publications
De Munnik M
(2023)
aß,a'ß'-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes
in Chemical Communications
Farley AJM
(2021)
Correction to "Structural Basis of Metallo-ß-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates".
in ACS infectious diseases
Salamaga B
(2021)
Demonstration of the role of cell wall homeostasis in Staphylococcus aureus growth and the action of bactericidal antibiotics.
in Proceedings of the National Academy of Sciences of the United States of America
Kidd SL
(2020)
Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion.
in Chemical science
Xiao YC
(2021)
Design and enantioselective synthesis of 3-(a-acrylic acid) benzoxaboroles to combat carbapenemase resistance.
in Chemical communications (Cambridge, England)
Qingfeng Hu
(2019)
Detection of "Hidden" Antimicrobial Drug Resistance
in ACS Infectious Disease
Hu Q
(2019)
Detection of "Hidden" Antimicrobial Drug Resistance.
in ACS infectious diseases
Hind CK
(2019)
Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens.
in Antimicrobial agents and chemotherapy
Newman H
(2021)
High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding Modes.
in Journal of medicinal chemistry
De Munnik M
(2023)
High-throughput screen with the l,d-transpeptidase LdtMt2 of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors.
in Chemical science
Bloom G
(2019)
Next steps towards universal health coverage call for global leadership
in BMJ
Dowson AJ
(2022)
Plant peptidoglycan precursor biosynthesis: Conservation between moss chloroplasts and Gram-negative bacteria.
in Plant physiology
Sutton J
(2021)
Staphylococcus aureus cell wall structure and dynamics during host-pathogen interaction
in PLOS Pathogens
Farley AJM
(2021)
Structural Basis of Metallo-ß-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates.
in ACS infectious diseases
Lang PA
(2021)
Structural Investigations of the Inhibition of Escherichia coli AmpC ß-Lactamase by Diazabicyclooctanes.
in Antimicrobial agents and chemotherapy
Hao M
(2022)
Structures of Class I and Class II Transcription Complexes Reveal the Molecular Basis of RamA-Dependent Transcription Activation.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Tooke CL
(2023)
Tautomer-Specific Deacylation and O-Loop Flexibility Explain the Carbapenem-Hydrolyzing Broad-Spectrum Activity of the KPC-2 ß-Lactamase.
in Journal of the American Chemical Society
Husain L
(2020)
The China-UK Global Health Support Programme: looking for new roles and partnerships in changing times.
in Global health research and policy
Maxwell A
(2019)
The Molecular Basis of Antibiotic Action and Resistance.
in Journal of molecular biology
Description | We have established an open source antibiotic discovery platform with academic and industry partners: providing a full breadth of expertise and reagents from previous discovery programs. However, the major exchange program planned as part of this UK CHNA collaboration has had to be put on hold due to COVID-19. This has held back UK CHINA collaborations and a no cost extension will be sought to help meet currently unmet deliverables |
Exploitation Route | This early stage discovery program represents a a step change in how antibiotic discovery might progress. |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
URL | https://github.com/opensourceantibiotics |
Description | Research consortium has been an essential component in the establishment of open source antibiotic discovery https://github.com/opensourceantibiotics Policy impact https://www.researchgate.net/publication/369169934_AMR_policy_dialogue_driving_innovative_solutions_for_antimicrobial_discovery |
First Year Of Impact | 2020 |
Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
Impact Types | Cultural |
Description | ASIA-EUROPE Foundation Universal Health Coverage in an era of antimicrobial resistance (AMR) and pandemics |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://asef.org/projects/2023-uhc-in-an-era-of-amr-and-pandemics-conference/ |
Description | Enabling public and private partnership platforms to accelerate antibiotic discovery |
Amount | £41,151 (GBP) |
Funding ID | 72691 EPSRC IAA Warwick |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2022 |
End | 06/2022 |
Description | Japan-UK AMR - fostering the next generation of antibiotic discovery |
Amount | £1,600,000 (GBP) |
Organisation | The Great Britain Sasakawa Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2023 |
End | 11/2029 |
Description | Mapping capabilities and developing policy positions to influence funding and practice to develop and strengthen the pipeline of AMR discovery R&D in UK and China |
Amount | £64,000 (GBP) |
Funding ID | 72259 |
Organisation | United Kingdom Research and Innovation |
Sector | Public |
Country | United Kingdom |
Start | 01/2022 |
End | 03/2022 |
Description | Strengthening China-UK Global Development Knowledge, Co-operation and Effectiveness A Research and Learning Platform for China International Development Research Network (CIDRN) Phase II |
Amount | £645,000 (GBP) |
Organisation | UK Department for International Development |
Sector | Public |
Country | United Kingdom |
Start | 04/2019 |
End | 03/2022 |
Description | Asia Europe Foundation |
Organisation | Asia–Europe Foundation (ASEF) |
Country | Singapore |
Sector | Charity/Non Profit |
PI Contribution | ASEF funded the participation of Gerry Bloom in the World AMR Conference in Washington in September 2022 at which he helped facilitate a panel on AMR and UHC. ASEF then organised a meeting in London to discuss a planned international workshop on AMR in Tokyo in February 2023. It funded the participation of Chris Dowson and Gerry Bloom at the workshop in Tokyo at which Chris Dowson was on a panel on innovative approaches to drug discovery and Gerry Bloom faciliated a panel on AMR and UHC and a final session to agree key recommendations to policy makers. |
Collaborator Contribution | ASEF organised a major workshop in Tokyo that brought together policy-makers, researchers and private companies from a number of countries in Asia and Europe. Through its links with the Ministry of Foreign Affairs in Japan, it make the final report available to the team preparing for the meeting of the G7 in May 2023 |
Impact | The major output is the report on the Tokyo Workshop. |
Start Year | 2022 |
Description | Astra Zeneca inhibitor development |
Organisation | AstraZeneca |
Department | Astra Zeneca |
Country | United States |
Sector | Private |
PI Contribution | Biochemical assay development and antimicrobial assays |
Collaborator Contribution | Development of an provision of target directed compound library and compounds with bioactivity |
Impact | Establishment of an open source discovery collaboration with industry engagement |
Start Year | 2020 |
Description | Establishment of an open source antibiotic discovery consortium |
Organisation | Diamond Light Source |
Country | United Kingdom |
Sector | Private |
PI Contribution | Biochemical assay development |
Collaborator Contribution | Gene cloning, optimisation, expression, protein production and crystallography |
Impact | Step change in international scientific collaboration : open source discovery with free exchange of ideas and results |
Start Year | 2020 |
Description | Establishment of an open source antibiotic discovery consortium |
Organisation | Northeastern University - Boston |
Country | United States |
Sector | Academic/University |
PI Contribution | Biochemical assay development |
Collaborator Contribution | Gene cloning, optimisation, expression, protein production and crystallography |
Impact | Step change in international scientific collaboration : open source discovery with free exchange of ideas and results |
Start Year | 2020 |
Description | Establishment of an open source antibiotic discovery consortium |
Organisation | Seattle Biomedical Research Institute |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | Biochemical assay development |
Collaborator Contribution | Gene cloning, optimisation, expression, protein production and crystallography |
Impact | Step change in international scientific collaboration : open source discovery with free exchange of ideas and results |
Start Year | 2020 |
Description | Establishment of an open source antibiotic discovery consortium |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Biochemical assay development |
Collaborator Contribution | Gene cloning, optimisation, expression, protein production and crystallography |
Impact | Step change in international scientific collaboration : open source discovery with free exchange of ideas and results |
Start Year | 2020 |
Description | Life Arc inhibitor development |
Organisation | LifeArc |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Development of biochemical assays, microbiology and structural biology |
Collaborator Contribution | Design development and provision of targeted chemical libraries including identification of bioactive molecules |
Impact | Establishment of industry interaction with an open source antibiotic discovery platform: scientific cultural change |
Start Year | 2020 |
Description | New academic Collaboration : NEU USA |
Organisation | Northeastern University - Boston |
Country | United States |
Sector | Academic/University |
PI Contribution | Development of new biochemical assays |
Collaborator Contribution | Computational chemistry design of novel antimicrobial inhibitors and provision of follow up medicinal chemistry |
Impact | Grant applications for follow up funding and establishment of an open source antibiotic discovery platform |
Start Year | 2020 |
Description | New academic Collaboration : Shanghai Jiao Tong University |
Organisation | Shanghai Jiao Tong University |
Country | China |
Sector | Academic/University |
PI Contribution | Access to results and reagents for a joint collaborative project |
Collaborator Contribution | New antimicrobial reagents requiring characterisation of mode and molecular mechanism of action |
Impact | Planned exchage of reagents and personnel. Funding has been acquired within China to enable this. |
Start Year | 2019 |
Description | Research and Learning Platform for China International Development Research Network (CIDRN) |
Organisation | China Agricultural University (CAU) |
Country | China |
Sector | Academic/University |
PI Contribution | We prepared a successful bid for funding by DFID and are focusing on building a network of partners in the UK and Europe to collaborate with a network of partners in China. |
Collaborator Contribution | The China Agricultural University is coordinating a network of partners in China with the aim of building China-UK joint research on areas of mutual interest. |
Impact | This is a multi-disciplinary partnership which includes several social sciences in addition to agricultural science, public health and public administration. |
Start Year | 2019 |
Description | "Strengthen Multilateral Cooperation, Promote Better Global Health" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Presentation by Lewis Husain to inform understanding and research / advisory work by key think tanks in China and central government. |
Year(s) Of Engagement Activity | 2020 |
Description | 2022-2023 Warwick Chemical Biology Lecture |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | This lectureship aims to bring leading Chemical Biologists to the University of Warwick to deliver a seminar on their research and spend the day discussing science with faculty and students |
Year(s) Of Engagement Activity | 2023 |
URL | https://warwick.ac.uk/fac/sci/chemistry/ |
Description | AMR Policy Dialogue: Driving Innovative Solutions for Antimicrobial Discovery |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Workshop to discuss research on efforts to promote R&D for novel antimicrobials in UK and China and policy/research implications. |
Year(s) Of Engagement Activity | 2022 |
Description | Cambridge Infectious Diseases Annual symposium |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Combating infectious diseases remains as important as ever. A combination of basic and applied research has historically led to some extraordinary success stories, such as the eradication of smallpox. Yet, recent events remind us that the emergence of a new infectious disease can rapidly traverse contents and threaten the health of the population on a global scale. With a society fighting a viral pandemic and the increasing concern of drug-resistant pathogens, infectious disease researchers face plenty of challenges that require coordinated networks of scientists and institutions. Title: Connecting Synthetic Chemistry and Clinically Relevant Microbiology |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.infectiousdisease.cam.ac.uk/programme-cid-annual-symposium-2023 |
Description | Croucher Advanced Study Institute 2021 - Metals in Biology and Medicine: From Molecular Imaging to Drug Resistance |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | This course aims to disseminate the cutting-edge research about metals in biology and medicine to Hong Kong. The exploration of metals in biology and medicine is a fast-growing research area. Over the past decades, copper, iron and zinc have attracted enormous attentions due to the involvement of metals in aging and neuroscience. These metals can be detected and monitored in vivo by multi-techniques and multi-omics approaches, which further our understanding in metal homeostasis and metals in pathophysiological processes. This workshop aims to share some insightful views and ideas in molecular imaging and biosensing, metals in medicine, antibiotics and drug resistance |
Year(s) Of Engagement Activity | 2021 |
URL | https://chemistry.hku.hk/events/seminars_conferences_detail/175/ |
Description | Danish Society for Medicinal Chemistry and Chemical Biology Symposium |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | This full day symposium builds on the successful inaugural symposium in 2018. Jointly organised by the Danish Society for Medicinal Chemistry and Chemical Biology and the Center for Medicinal Chemistry at the University of Copenhagen, the meeting features and takes place in Haderup Auditorium 4, Panum Institute, Blegdamsvej 3B, 2100 Copenhagen. Title: Enmetazobactam and the mechanisms of widely used ß-lactamase inhibitors |
Year(s) Of Engagement Activity | 2023 |
URL | http://dsmkb.dk/en/symposium-jan-27th-2023/ |
Description | Engagement with UK Embassy to China on China and global health, including AMR |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | LH was consulted on China and global health issues by UK embassy to China. Led to ongoing discussion and collaboration with DHSC and Chinese Centre for International Knowledge on Development (CIKD) on UK-China AMR cooperation. |
Year(s) Of Engagement Activity | 2022 |
Description | Engagement with Wellcome Trust re China and antimicrobial R&D |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | Discussion with major funder of China's R&D for antimicrobials and international engagement on AMR. |
Year(s) Of Engagement Activity | 2022 |
Description | High level meeting in Tokyo of Asian and European experts on antt-microbial resistance |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Christopher Dowson and Gerald Bloom participated in a meeting on Universal Health Coverage in an era of Antimicrobial Resistance and Pandemics hosted by the Asia Europe Foundation, the AMR Clinical Reference Centre and the Ministry of Foreign Affairs of Japan. Prof. Dowson participated in a panel on addressing Drug Discovery and Prof. Bloom facilitated two sessions and drafted the final report. The final report will be shared with the team preparing the documents and addressing AMR for the forthcoming meeting of the G7 in Japan. |
Year(s) Of Engagement Activity | 2023 |
Description | IDS Blog on China and the future of global governance |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Blog published on the IDS website on China and the Future of Global Governance |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.ids.ac.uk/opinions/china-and-the-future-of-global-health-governance/ |
Description | Influence BBC journalist to make radio programme on AMR in the marine environment |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Lewis Husain persuaded a BBC journalist to make a radio 4 programme on AMR in the marin environment, an ignored topic, and supported development of the concept |
Year(s) Of Engagement Activity | 2020 |
URL | http://www.bbc.co.uk/programmes/m000mr6r |
Description | Institute of Pharmaceutical Science - IPS Seminar Series - King's College London |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | The seminars, hosted by Principal Investigators within the Departments, serve as a knowledge transfer and ideas exchange hub for researchers and academics within IPS, in addition to fostering new collaborations within and outside the Institute at a national and international level. Title 'Metalloenzymes- from mechanisms to medicines' |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.kcl.ac.uk/events/series/institute-of-pharmaceutical-science-seminar-series |
Description | International symposium on anti-TB biology and therapeutics |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | International symposium on anti-TB biology and therapeutics Title 'Metalloenzymes- from mechanisms to medicines' |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.medicilon.com/market-activities/anti-tb-symposium-2023/ |
Description | Natural Products, Students Against Superbugs Africa (SASA) webinar on AMR and drug development, 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | Students Against Superbugs (SAS) Africa is a student-driven initiative under the guidance of qualified health professionals which seeks to mitigate the threat of Antimicrobial Resistance (AMR) in African communities using a One Health Approach with a keen focus on rural areas and urban informal settlements. We do this by empowering young people throughout Africa to be lead advocates in the fight against AMR. Young people account for majority of the population and are the future global leaders and stakeholders. Their active participation will play a huge role in curtailing this health burden. It is imperative that they are made aware of it early enough, and nurtured to help in transiting appropriate knowledge, attitudes, and practices to their respective communities. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.studentsagainstsuperbugs.org/ |
Description | Participation in WHO Western Pacific Regional Innovation Forum and Platform |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lewis Husain participated in workshop aimed at strengthening understanding of innovation and health in the Western Pacific region and development of an agenda for increased regional cooperation. |
Year(s) Of Engagement Activity | 2020 |
Description | Policy briefing - Developing Health Diplomacy Capacity to Support Public Health in a Rapidly Changing World |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Policy briefing circulated to inform understanding and research / advisory work of key think tanks in China and to central government. |
Year(s) Of Engagement Activity | 2020 |
Description | Radley College Lecture |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Lecture topic - From Penicillins to Sensing Oxygen |
Year(s) Of Engagement Activity | 2021 |
Description | Technical Support to an Evaluation of Ten Years of China's Health Reform |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Gerald Bloom and Wang Chenguang provided technical inputs to a major evaluation of ten years of China's health reform undertaken by the Government of China, the World Health Organization and the World Bank. A draft report is under review. The current plan is to publish the report for wide distribution in China and internationally. Gerald Bloom, co-authored a background paper on lessons emerging from international experience, including the increasing importance of digital health services and he helped produce a final draft report. Wang Chenguang led a team that assessed governance arrangements for implementing a major health system change process. |
Year(s) Of Engagement Activity | 2019 |
Description | Towards world changing antibiotics, Janssen Research & Development, WHO World Antimicrobial Awareness Week, 2021 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | World Antimicrobial Awareness Week (WAAW) is celebrated from 18-24 November every year. The 2021 theme, Spread Awareness, Stop Resistance, called on One Health stakeholders, policymakers, health care providers, and the general public to be Antimicrobial Resistance (AMR) Awareness champions. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.who.int/campaigns/world-antimicrobial-awareness-week/2021 |
Description | UK CHINA: CHNUK virtual workshops and research seminar series |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Presentation/ discussion with Brazilian microbiology groups as to how develop and work effectively as national and international consortia in AMR discovery |
Year(s) Of Engagement Activity | 2020 |
Description | UK CHINA: CHNUK virtual workshops and research seminar series |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | To develop and deepen UK CHINA AMR discovery links both within the participants of Integrate CHNUK, other UK China and UK international research consortia, policy makers and the third sector. Looking for new ways of working and funding AMR research |
Year(s) Of Engagement Activity | 2020,2021 |
Description | meeting with Department of Global Health at China National Health and Development Research Centre |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | On September 19, 2019 Gerald Bloom and Lewis Husain met with members of the Department of Global Health of the China National Health and Development Centre to discuss lessons learned about the design of activities for mutual learning between China and other countries on global health.The purpose of the meeting was to enable the participants in the discussion to draw on past experiences in designing a programme of work on this topic in collaboration with the Government. This will influence China's engagement in the health sector of a number of DAC-eligible countries in Africa and Asia. |
Year(s) Of Engagement Activity | 2019 |
Description | participation in a research and innovation expert meeting convened by the Sino-European Health Networking Hub |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Gerald Bloom and Lewis Husain were invited to participate in an expert consultation about joint European-Chinese health research and priorities for future funding. The consultation is part of a process for developing recommendations for the European Union. |
Year(s) Of Engagement Activity | 2020 |